RT Journal Article
T1 p38γ is essential for cell cycle progression and liver tumorigenesis
A1 Tomás Loba, Antonia
A1 Manieri, Elisa
A1 González Terán, Bárbara
A1 Mora, Alfonso
A1 Leiva Vega, Luis
A1 Santamans, Ayelén M.
A1 Romero-Becerra, Rafael
A1 Rodríguez, Elena
A1 Pintor Chocano, Aránzazu
A1 Feixas, Ferran
A1 López, Juan Antonio
A1 Caballero, Beatriz
A1 Trakala, Marianna
A1 Blanco, Óscar
A1 Torres, Jorge L.
A1 Hernández Cosido, Lourdes
A1 Montalvo Romeral, Valle
A1 Matesanz, Nuria
A1 Roche Molina, Marta
A1 Bernal, Juan Antonio
A1 Mischo, Hannah
A1 León, Marta
A1 Caballero, Ainoa
A1 Miranda-Saavedra, Diego
A1 Ruiz-Cabello Osuna, Jesús
A1 Nevzorova, Yulia
A1 Cubero Palero, Francisco Javier
A1 Bravo, Jerónima
A1 Vázquez, Jesús
A1 Malumbres, Marcos
A1 Marcos, Miguel
A1 Osuna, Silvia
A1 Sabio, Guadalupe
AB The cell cycle is a tightly regulated process that is controlled by the conserved cyclin-dependent kinase (CDK)–cyclin protein complex1. However, control of the G0-to-G1 transition is not completely understood. Here we demonstrate that p38 MAPK gamma (p38γ) acts as a CDK-like kinase and thus cooperates with CDKs, regulating entry into the cell cycle. p38γ shares high sequence homology, inhibition sensitivity and substrate specificity with CDK family members. In mouse hepatocytes, p38γ induces proliferation after partial hepatectomy by promoting the phosphorylation of retinoblastoma tumour suppressor protein at known CDK target residues. Lack of p38γ or treatment with the p38γ inhibitor pirfenidone protects against the chemically induced formation of liver tumours. Furthermore, biopsies of human hepatocellular carcinoma show high expression of p38γ, suggesting that p38γ could be a therapeutic target in the treatment of this disease.
PB Nature Research
SN 1476-4687
YR 2019
FD 2019-04-10
LK https://hdl.handle.net/20.500.14352/13634
UL https://hdl.handle.net/20.500.14352/13634
LA eng
NO Tomás Loba, A., Manieri, E., González terán, B. et al. «P38γ Is Essential for Cell Cycle Progression and Liver Tumorigenesis». Nature, vol. 568, n.o 7753, abril de 2019, pp. 557-60. DOI.org (Crossref), https://doi.org/10.1038/s41586-019-1112-8.
NO Unión Europea (H2020 y FP7)
NO Ministerio de Economía y Competitividad (MINECO) / FEDER
NO Comunidad de Madrid
NO Juan de la Cierva/Ministerio de Economía, Comercio y Empresa (España)
NO Ministerio de Ciencia, Innovación y Universidades (España)
NO German Research Foundation
NO The European Foundation for the Study of Diabetes
NO BBVA Foundation
NO Ramón y Cajal
NO Fundación Ramón Areces/Universidad Autónoma de Madrid
NO The Alan Morement Memorial Fund
NO Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional
NO La Caixa
NO Centro de Excelencia Severo Ochoa
NO Fundación La Marató / Fundación ‘La Caixa’
NO Junta de Castilla y León
DS Docta Complutense
RD 3 abr 2026